Qyuns Therapeutics Co., Ltd. (HKG: 2509) announced that China’s National Medical Products Administration (NMPA) has...
Qyuns Therapeutics Co., Ltd. (HKG: 2509) today announced a global exclusive collaboration and licensing agreement with F. Hoffmann‑La...
On August 26, 2025, Hong Kong‑listed China-based InxMed (Nanjing) Co., Ltd (HKG: 2509) announced that it has...
China-based Jiangsu QYuns Therapeutics Co., Ltd (HKG: 2509) announced that QX004N, an interleukin-23 subunit p19...
China-based Jiangsu QYuns Therapeutics Co., Ltd (HKG: 2509) has entered into a licensing agreement with...
China-based Jiangsu QYuns Therapeutics Co., Ltd (HKG: 2509) announced that its Phase III study of...
Huadong Medicine Co., Ltd (SHE: 000963) announced that another indication approval filing for its SaiYueXin,...
Huadong Medicine Co., Ltd (SHE: 000963) has announced that the National Medical Products Administration (NMPA)...
Huadong Medicine Co., Ltd (SHE: 000963), a China-based pharmaceutical company, has announced that it has...
Jiangsu QYuns Therapeutics Co., Ltd (HKG: 2509), a biopharmaceutical company based in China, has entered...
Jiangsu QYuns Therapeutics Co., Ltd (HKG: 2509), a biopharmaceutical company based in China, has announced...
Jiangsu QYuns Therapeutics Co., Ltd (HKG: 2509), a biopharmaceutical company based in China, has announced...
Jiangsu QYuns Therapeutics Co., Ltd. (HKG: 2509), based in China, is poised to launch an...
China-based Jiangsu QYuns Therapeutics Co., Ltd (HKG: 2509) has announced its intention to pursue an...